About Partitioning defective 3 homolog B
Partitioning defective 3 homolog B (PARD3B) is a protein
from Homo sapiens identified by UniProt accession
Q8TEW8, 1205 residues long.
MolForge cross-references it against 0 known binders and
88 disease associations.
Target properties
| Protein name | Partitioning defective 3 homolog B |
|---|
| UniProt accession | Q8TEW8 |
|---|
| Gene | PARD3B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1205 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (88)
Diseases linked to this target (Open Targets).
- body mass index · score 0.42
- lean body mass · score 0.41
- body fat percentage · score 0.40
- intraocular pressure measurement · score 0.39
- fat body mass · score 0.39
- cortical surface area measurement · score 0.37
- body weight · score 0.36
- sex hormone-binding globulin measurement · score 0.33
- triglyceride measurement · score 0.32
- DNA methylation · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8TEW8-F1 | alphafold | PREDICTED | 55.28 | — |
Amino-acid sequence (1205 residues)
MKVTVCFGRT GIVVPCKEGQ LRVGELTQQA LQRYLKTREK GPGYWVKIHH LEYTDGGILD PDDVLADVVE DKDKLIAVFE EQEPLHKIES PSGNPADRQS PDAFETEVAA QLAAFKPIGG EIEVTPSALK LGTPLLVRRS SDPVPGPPAD TQPSASHPGG QSLKLVVPDS TQNLEDREVL NGVQTELLTS PRTKDTLSDM TRTVEISGEG GPLGIHVVPF FSSLSGRILG LFIRGIEDNS RSKREGLFHE NECIVKINNV DLVDKTFAQA QDVFRQAMKS PSVLLHVLPP QNREQYEKSV IGSLNIFGNN DGVLKTKVPP PVHGKSGLKT ANLTGTDSPE TDASASLQQN KSPRVPRLGG KPSSPSLSPL MGFGSNKNAK KIKIDLKKGP EGLGFTVVTR DSSIHGPGPI FVKNILPKGA AIKDGRLQSG DRILEVNGRD VTGRTQEELV AMLRSTKQGE TASLVIARQE GHFLPRELKG EPDCCALSLE TSEQLTFEIP LNDSGSAGLG VSLKGNKSRE TGTDLGIFIK SIIHGGAAFK DGRLRMNDQL IAVNGESLLG KSNHEAMETL RRSMSMEGNI RGMIQLVILR RPERPMEDPA ECGAFSKPCF ENCQNAVTTS RRNDNSILHP LGTCSPQDKQ KGLLLPNDGW AESEVPPSPT PHSALGLGLE DYSHSSGVDS AVYFPDQHIN FRSVTPARQP ESINLKASKS MDLVPDESKV HSLAGQKSES PSKDFGPTLG LKKSSSLESL QTAVAEVRKN DLPFHRPRPH MVRGRGCNES FRAAIDKSYD GPEEIEADGL SDKSSHSGQG ALNCESAPQG NSELEDMENK ARKVKKTKEK EKKKEKGKLK VKEKKRKEEN EDPERKIKKK GFGAMLRFGK KKEDKGGKAE QKGTLKHGGL REEELEKMKE ERERIGAKHQ ELREKQARGL LDYATGAIGS VYDMDDDEMD PNYARVNHFR EPCTSANVFR SPSPPRAGPF GYPRDGHPLS PERDHLEGLY AKVNKPYHPL VPADSGRPTG GSTDRIQKLR KEYYQARREG FPLYEDDEGR ARPSEYDLLW VPGRGPDGNA HNLRFEGMER QYASLPRGGP ADPVDYLPAA PRGLYKEREL PYYPGAHPMH PPKGSYPRPT ELRVADLRYP QHYPPPPAPQ HKGPFRQDVP PSPPQHQRMP AYQETGRPGP RGGSPDQYPY RTQDSRQKNP MTAAV
Explore Partitioning defective 3 homolog B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets